Skip to main content
OpenTrials

Clinical trial condition

Metastatic Renal Cell Carcinoma

Explore clinical trials studying Metastatic Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

126 public trials 24 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Renal Cell Carcinoma trial results

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, not recruiting

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

NCT06132945

Conditions
Adenocarcinoma, Brain Diseases, Brain Metastases, +21 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities) Commack, New York, United States
View Trial Details
Active, not recruiting

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +47 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
View all 13 locations
View Trial Details
Active, not recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

NCT05219318

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • CH de la Cote Basque - Service d'Oncologie Bayonne, France
  • CHU de Bordeaux - Service d'Oncologie Bordeaux, France
  • Centre François Baclesse - Service d'Oncologie Caen, France
  • Centre Jean Perrin - Service d'Oncologie Clermont-Ferrand, France
View all 26 locations
View Trial Details
Completed

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

NCT04090710

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Peter MacCallum Cancer Centre Melbourne, Australia
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Juravinski Cancer Centre Hamilton, Ontario, Canada
  • Grand River Regional Cancer Centre Kitchener, Ontario, Canada
View Trial Details

Related conditions